Last edition
News about
Roche Boosts AI Muscle with Nvidia Chip Expansion to Accelerate Drug Discovery
Swiss pharma major Roche has significantly expanded its artificial intelligence (AI) capabilities by deploying thousands of advanced GPUs from Nvidia, marking one of the largest AI infrastructure investments in the pharmaceutical sector.
The Guru Nanak Institute of Pharmacy (GNIP), located in Dalewal, Hoshiarpur district, Punjab, hosted a two-day national conference focused on the theme ‘Next-Gen Pharma Trends towards Viksit Bharat.’
EU Approves Imfinzi as First Perioperative Immunotherapy for Gastric and Gastroesophageal Cancers
The EU approval of Imfinzi is based on phase-III MATTERHORN trial results, which showed significant improvements in event-free and overall survival in early-stage gastric and gastroesophageal cancer patients.
EBGLYSS Achieves Phase-III Success in Children with Moderate-to-Severe Atopic Dermatitis
In phase-III ADorable-1 study, EBGLYSS demonstrated strong efficacy in paediatric atopic dermatitis. The treatment also showed meaningful gains in higher efficacy endpoints and itch relief, alongside a safety profile consistent with previous studies and no reported injection site pain.
UK Health Security Agency and Stablepharma report positive Phase I results for SPVX02, a fridge-free Tetanus and Diphtheria vaccine stable at 30°C for 24 months.
Argo Biopharma's siRNA Therapy BW-20805 Gets FDA Fast Track for HAE
Argo Biopharma has received FDA Fast Track designation for BW-20805, with an ongoing global phase-II study in adult HAE patients and primary completion expected in the second half of 2026.
National Institutes of Health Develops AI Tool to Predict Risk of Intimate Partner Violence
Researchers funded by National Institutes of Health have developed an AI-based clinical decision tool that predicts risk of Intimate Partner Violence using routine healthcare data with high accuracy.
Shanghai UniXell Biotechnology. has received US Food and Drug Administration IND clearance for UX-GIP001, marking the first iPSC-derived allogeneic cell therapy to enter clinical trials for Epilepsy in the US.
Merck Showcases New Cardio-Pulmonary Data at ACC.26
Merck presented late-breaking data from phase-III and phase-II trials at ACC.26, highlighting advances in its cardio-pulmonary pipeline, including an investigational oral PCSK9 inhibitor and therapies for pulmonary hypertension.
The US FDA has accepted Sun Pharma’s supplemental BLA for ILUMYA to treat active psoriatic arthritis in adults, with a decision expected by 29 October, 2026, potentially expanding its IL-23 inhibitor portfolio.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy